Nach Biontechs Curevac-Übernahme: So ist der Stand beim Bebauungsplan für Görzhausen III. Marburg. Während die Zukunft von ...

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...

MAINZ, Germany, February 2, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company’s first proprietary plasmid DNA manufacturing facility ...

MAINZ, GERMANY, February 10, 2021 (GLOBE NEWSWIRE) - We started the manufacturing process at the Marburg facility with the execution of the first step: the production of mRNA, which is the active ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. BERLIN (AP) — German vaccine maker BioNTech, ...

MAINZ, Germany, February 16, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable ...

Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs The new plasmid manufacturing facility aims to increase BioNTech’s autonomy and flexibility in ...